2-(苄基氨基)乙醛 | 75971-37-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-(苄基氨基)乙醛
• 英文名称: 2-(N-benzylamino)acetaldehyde
• 英文别名: 2-(Benzylamino)acetaldehyde
• CAS: 75971-37-8
• 化学式: C₉H₁₁NO
• mdl: MFCD07368979
• 分子量: 149.192
• InChiKey: ONGYYRQSCJYQHL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  11
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (R,R)-2,3-di-O-isopropylidentartaric acid mono methyl ester 、 2-(苄基氨基)乙醛 在 硫酸 、 silica gel 作用下， 以 甲苯 为溶剂， 生成 methyl (1R,5S,7R)-3-benzyl-2-oxo-6,8-dioxa-3-azabicyclo[3.2.1]octane-7-exo-carboxylate
  参考文献：
  名称：

  Oligomers of Enantiopure Bicyclic γ/δ-Amino Acids (BTAa). 1. Synthesis and Conformational Analysis of 3-Aza-6,8-dioxabicyclo[3.2.1]octane-7-carboxylic Acid Oligomers (PolyBTG)

  摘要：

  A series of dimeric through pentameric oligomers of a bicyclic gamma/delta -amino acid (BTG) were synthesized using peptide coupling methods in solution with PyBroP or HATU. The analysis of H-1 NMR and Co spectra suggests that these oligomers could have a partially ordered structure in alcohol solutions.

  DOI：

  10.1021/ol006548s

文献信息

• [EN] TRICYCLIC ALKYNES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN<br/>[FR] ALCYNES TRICYCLIQUES QUI INTERAGISSENT AVEC LA PROTÉINE RÉGULATRICE DE GLUCOKINASE
  申请人：AMGEN INC

  公开号：WO2014035872A1

  公开（公告）日：2014-03-06

  The present invention relates to tricyclic alkyne compounds of formula I that interact with glucokinase regulatory protein. In addition, the present invention relates to methods of treating type 2 diabetes, and other diseases and/or conditions where glucokinase regulatory protein is involved using the compounds, or pharmaceutically acceptable salts thereof, and pharmaceutical compositions that contain the compounds, or pharmaceutically acceptable salts thereof.

  本发明涉及与葡萄糖激酶调节蛋白相互作用的式I的三环炔化合物。此外，本发明涉及使用这些化合物或其药学上可接受的盐治疗2型糖尿病和其他涉及葡萄糖激酶调节蛋白的疾病和/或症状的方法，以及含有这些化合物或其药学上可接受的盐的药物组合物。
• [EN] ORTHO-SUBSTITUTED BENZOIC ACID DERIVATIVES FOR THE TREATMENT OF INSULIN RESISTANCE<br/>[FR] DERIVES DE L'ACIDE BENZOIQUE ORTHO-SUBSTITUES DESTINES AU TRAITEMENT DE L'INSULINORESISTANCE
  申请人：ASTRAZENECA AB

  公开号：WO2004000294A1

  公开（公告）日：2003-12-31

  The present invention provides a compound of formula (I), wherein n is 0, 1 or 2; R1 represents halo, a C1-4alkyl group which is optionally substituted by one or more fluoro, a C1-4alkoxy group which is optionally substituted by one or more fluoro and wherein when n is 2 the substituents R1 may be the same or different; R2 represents an unbranched C2-7alkyl group; R3 represents H or OCH3; and W represents O or S and pharmaceutically acceptable salts and prodrugs thereof, to processes for preparing such compounds, to their utility in treating clinical conditions associated with insulin resistance, to methods for their therapeutic use and to pharmaceutical compositions containing them.

  本发明提供了一种式(I)化合物，其中n为0、1或2；R1代表卤素、可被一个或多个氟取代的C1-4烷基、可被一个或多个氟取代的C1-4烷氧基，且当n为2时，取代基R1可以相同或不同；R2代表直链C2-7烷基；R3代表H或OCH3；W代表O或S及其药学上可接受的盐和前药，以及制备此类化合物的方法，它们在治疗与胰岛素抵抗相关的临床条件中的用途，其治疗方法以及含有它们的药物组合物。
• [EN] NEW TRICYCLIC COMPOUNDS, PROCESS FOR THEIR MANUFACTURE AND THEIR USE AS LIGANDS OF THE BETA AMYLOID PEPTIDES<br/>[FR] NOUVEAUX COMPOSÉS TRICYCLIQUES, LEUR PROCÉDÉ DE FABRICATION ET LEUR UTILISATION EN TANT QUE LIGANDS DES PEPTIDES BÊTA-AMYLOÏDES
  申请人：UNI DEGLI STUDIO DI MILANO BICOCCA

  公开号：WO2012164476A1

  公开（公告）日：2012-12-06

  The synthesis and the use of the compounds with glycofused tricyclic structure as ligands of the Αβ peptides is the object of the invention. Such compounds result to be chemically stable, they have a high solubility under physiological conditions and they are suitable for functionalizations which make them easily conjugable to other entities to allow a therapeutic and diagnostic use thereof. The capability of the compounds to link the Αβ peptide, in the various shapes thereof, and in particular the most toxic one, represented by the oligomers, was evaluated through NMR experiments.(III).

  本发明的目标是合成和使用具有糖基融合三环结构的化合物作为Αβ肽配体。这些化合物具有化学稳定性，在生理条件下具有高溶解度，并且适合进行功能化，使它们易于与其他实体结合，以允许其进行治疗和诊断使用。通过NMR实验评估了这些化合物与Αβ肽的连接能力，特别是与寡聚体形式的最有毒的形式。
• Identification of kinase inhibitors
  申请人：Prescott C. John

  公开号：US20050084905A1

  公开（公告）日：2005-04-21

  The invention concerns the identification of protein kinase inhibitors that preferentially bind to the inactive conformation of a target protein kinase. The inhibitors are identified by locking the target protein kinase in an inactive conformation, and using Tethering to identify inhibitors preferentially targeting the inactive conformation.

  本发明涉及识别偏好结合到目标蛋白激酶的非活性构象的蛋白激酶抑制剂。该抑制剂通过将目标蛋白激酶锁定在非活性构象中，并使用Tethering技术识别偏好靶向非活性构象的抑制剂来确定。
• Extended tethering approach for rapid identification of ligands
  申请人：Erlanson A. Daniel

  公开号：US20050186630A1

  公开（公告）日：2005-08-25

  The invention concerns a method for rapid identification and characterization of binding partners for a target molecule, and for providing binding partners with improved binding affinity. More specifically, the invention concerns an improved tethering method for the rapid identification of at least two binding partners that bind near one another to a target molecule.

  该发明涉及一种快速鉴定和表征目标分子的结合伙伴，并提供具有改进结合亲和力的结合伙伴的方法。更具体地说，该发明涉及一种改进的束缚方法，用于快速鉴定至少两个结合伙伴，这些结合伙伴靠近目标分子。